Indicated for: hyperuricemia in tumor lysis syndrome
Route of administration: infusion
Substance: rasburicase (antineoplastic agent)
ATC: V03AF07 (Various | All other therapeutic products | Detoxifying agents for antineoplastic treatment)
This medicine may affect fertility.
Dose adjustment may be needed in liver disease.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Rasburicase is a medication used to treat high levels of uric acid in the blood (hyperuricemia) associated with tumor lysis syndrome, a common complication of cancer treatment. It works by converting uric acid into allantoin, a substance more easily excreted by the kidneys.
The medication is administered intravenously under the supervision of a specialist doctor, usually in a hospital setting. It is important to monitor uric acid levels and kidney function during treatment.
Side effects may include fever, nausea, vomiting, or injection site reactions. In rare cases, severe allergic reactions, such as anaphylactic shock, may occur, requiring immediate medical intervention.
Patients should inform their doctor about any other medications being used or pre-existing conditions, such as G6PD deficiency, to ensure the safe use of rasburicase.